^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
BAT1006
i
Other names: BAT1006
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Bio-Thera Solutions
Drug class:
HER2 inhibitor
Related drugs:
1m
A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic Tumors (clinicaltrials.gov)
P1/2, N=216, Recruiting, Bio-Thera Solutions | N=108 --> 216
Enrollment change • Combination therapy • Metastases
|
BAT1006 • BAT8010
5ms
A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic Tumors (clinicaltrials.gov)
P1/2, N=108, Recruiting, Bio-Thera Solutions | Not yet recruiting --> Recruiting | Trial primary completion date: May 2024 --> Dec 2024
Enrollment open • Trial primary completion date • Combination therapy • Metastases
|
BAT1006 • BAT8010
7ms
An Evaluation of BAT 8010 for Injection in Combination With BAT 1006 in Locally Advanced or Metastatic Entities Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of the Tumor in Patients Multicenter, Open Phase Ib/IIa Clinical Study (clinicaltrials.gov)
P1/2, N=108, Not yet recruiting, Bio-Thera Solutions
New P1/2 trial • Combination therapy • Metastases
|
BAT1006 • BAT8010
1year
Evaluating the Safety, Tolerability, and Pharmacokinetics of BAT1006 (clinicaltrials.gov)
P1, N=37, Active, not recruiting, Bio-Thera Solutions | Recruiting --> Active, not recruiting
Enrollment closed • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
BAT1006
over1year
Evaluating the Safety, Tolerability, and Pharmacokinetics of BAT1006 (clinicaltrials.gov)
P1, N=38, Recruiting, Bio-Thera Solutions | N=130 --> 38 | Trial completion date: Dec 2023 --> Mar 2025 | Trial primary completion date: Jun 2023 --> Aug 2024
Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
BAT1006
over1year
Evaluating the Safety, Tolerability, and Pharmacokinetics of BAT1006 (clinicaltrials.gov)
P1, N=130, Recruiting, Bio-Thera Solutions | N=24 --> 130
Enrollment change • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
BAT1006
over2years
Evaluating the Safety, Tolerability, and Pharmacokinetics of BAT1006 (clinicaltrials.gov)
P1, N=24, Recruiting, Bio-Thera Solutions
New P1 trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
BAT1006
Share via
